In the News
NEW YORK (GenomeWeb) – Arima Genomics is making a concerted push to expand its business into cancer diagnostics, following the demonstration of its sequencing-based chromosome conformation assay kits to identify cancer driver mutations.
To help with the effort, the Carlsbad, California-based firm is creating a clinical advisory board, led by New York University Langone Health molecular pathologist Matija Snuderl. His lab has partnered with Arima to develop a second-line diagnostic test to find cancer gene fusions and rearrangements missed by sequencing-based DNA and RNA assays. He will be joined by Darren Sigal, director of gastrointestinal oncology at MD Anderson Cancer Center, and Ken Young, director of hematopathology at Duke University.
More than half of patients fail to get a diagnostic result from DNA-based cancer panels, Snuderl said, and Hi-C assays can provide useful information — contributing to diagnosis, prognosis, or therapy selection — in about half of its use cases, a number based on non-yet-published results from a 220-patient cohort profiled at NYU and Memorial Sloan-Kettering Cancer Center.
In at least one pediatric case at NYU, Snuderl was able to identify a novel rearrangement in the PDL-1 gene in a brain tumor, which led to the patient’s treatment with immunotherapy.